Abstract: There is provided a method of preparing an unsaturated fatty acid dry concentrate, wherein a substance comprising at least one unsaturated fatty acid is applied on a biologically inert matrix having a large surface area and is subsequently dried, as well as a composition comprising at least one unsaturated fatty acid and foods, beverages, drugs comprising this composition.

Abstract: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging.

Abstract: A product has solid stable water clusters including a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having a permanent electric dipole moment with an electrical field surrounding the solid stable water clusters.

Abstract: The subject matter of the present invention is marked inorganic additives, a method for their production and also their use.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.

Abstract: A composite material formulated for slow release of a small molecule in seawater includes a porous inorganic oxide framework and micelles embedded within the pores of the framework. The micelles include a surfactant and a small molecule, the surfactant being present in the composite material at no more than 80 parts by weight per 100 parts by weight inorganic oxide, the composite material being stable in seawater for releasing the small molecule over at least 20 days.

Abstract: The present disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based jelly composition comprising; vegetable derived glycerine and an emulsifier, wherein the emulsifier can be any known and/or commercially available glucoside containing emulsifier. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may also be added to the jelly to impart fragrance, color, UVA and UVB sun protection factor(s), immuno-enhancing aromatherapeutics, as well as free radical scavenging constituents. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture as required. The glycerine is preferably present in the range of 50-95%.

Abstract: A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement.

Abstract: A novel three-component synergistic preservative system has zinc oxide, a phenoxyethanol component, and caprylyl glycol. The preservative system provides sufficient preservative activity without the use of other preservatives such as parabens. It provides broad spectrum activity against yeast and molds, and remains effective long term.

Abstract: A method to prepare new morphologies, especially vesicle-type, of carbon nanotubes (CNT) by supramolecular interactions between them and dendritic or linear-dendritic polymers and copolymers. Due to their water solubility, high functionality and unique properties, the prepared hybrid nanomaterials have excellent applicability in different fields especially in nanomedicine in comparison with usual CNTs.

Abstract: The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to anemulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C1-C6) alkyl esters of the aforementioned acids, or mixtures thereof, and wherein the oil phase comprises at least one membrane-forming substance forming a lamellar arranged membrane in the emulsion.

Abstract: The present invention relates to a Carnallite salt preparation useful in edible products, such as a food, beverage, dietary supplement, oral care, nutraceutical pet food, animal feed, pharmaceutical and other edible products. The Carnallite salt preparation of the invention is without high levels of sodium chloride and notably low in bromide. The Carnallite salt preparation may be a food grade product with dietary acceptable bromide levels. The present invention further relates to edible products comprising the Carnallite salt preparation, such as reduced sodium food products.

Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.

Abstract: Nanomaterials of the JT phase of the titanium oxide TiO2-x, where 0?x?1 having as a building block a crystalline structure with an orthorhombic symmetry and described by at least one of the space groups 59 Pmmn, 63 Amma, 71 Immm or 63 Bmmb. The nanomaterials are in the form of nanofibers, nanowires, nanorods, nanoscrolls and/or nanotubes and are obtained from a hydrogen titanate and/or a mixed sodium and hydrogen titanate precursor compound that is isostructural to the JT crystalline structure. The titanates are the hydrogenated, the protonated, the hydrated and/or the alkalinized phases of the JT crystalline phase that are obtained from titanium compounds such as titanium oxide with an anatase crystalline structure, amorphous titanium oxide, and titanium oxide with a rutile crystalline structure, and/or directly from the rutile mineral and/or from ilmenite.

Abstract: The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.

Abstract: This invention relates to compositions which are capable of sequestering calcium ions and are derived in part from renewable carbohydrate feedstocks. The calcium sequestering compositions are mixtures containing one or more hydroxycarboxylic acid salts and one or more aluminum salts.

Abstract: A cosmetic composition in the form of an O/W emulsion includes: (A) 1 to 20% by weight of a plate-like powder that has been surface-treated with an alkylalkoxysilane, (B) 0.1 to 10% by weight of an oil that is solid at a temperature of 25° C., (C) 0.3 to 50% by weight of an oil selected from the group consisting of a hydrocarbon oil, an ester oil, and an ether oil, each having a viscosity of 500,000 mPa·s or less at a temperature of 25° C., (D) 0.1 to 20% by weight of a nonionic surfactant having an HLB value of 8 or less, (E) 0.05 to 10% by weight of a water-soluble polymer having a hydrocarbon group with a carbon number of 8 to 30 and an anionic group in a molecule thereof, and (F) water.

Abstract: An object of the present invention is to provide an antiviral agent which exhibits high antiviral activity even under irradiation with visible light and is capable of detoxifying a virus. The antiviral agent according to the present application is composed of a dispersion containing noble metals and photocatalyst particles as supported by the noble metals, the dispersion containing 0.01 part by mass to 1 part by mass of noble metal atoms based on 100 parts by mass of photocatalyst particles.

Abstract: A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time.

Abstract: Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least multivalent metal compound, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive strength in both wet and dry environments which exhibit bond strength upon curing with the possible usage as bone cement for bone filler applications.

Abstract: A cosmetic preparation characterized by excellent adhesion at the place of application, comprises at least one silsesquioxane wax.

Abstract: An adjuvant composition is provided which comprises: (a) at least one water-soluble electrolyte; (b) at least one electrolyte-tolerant surfactant; (c) antifoam component which is at least one mixture selected from the group consisting of (1) at least one branched silicone resin (i), at least one silicone fluid (ii), at least one particulate metal oxide (iii) and, optionally, at least one catalyst (iv) for catalyzing the condensation of siloxy groups, (2) the equilibration reaction product of mixture (1), and (3) mixture (1) in which at least a portion of particulate metal oxide (iii) is pre-hydrophobized; (d) optionally, at least one additional bioinert material; and, (e) water.

Abstract: There is provided a surface-active material that comprises fibers which have been modified so as to impart surface-active properties onto said fibres and giving it a contact angle between 60° and 120°, wherein the fibres have an aspect ratio of more than 10 to 1,000. The surface-active material can be used for foam and emulsion formation and stabilization, coatings, encapsulation and drug delivery. It can for example be used in the following industries: foods, home and personal care, oilfield, agriculture, textile, construction, emulsion polymerization, leather, plastic, pulp, paper and pharma.

Abstract: An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, and a diffraction intensity ratio, an R value, determined by an equation (1): R=(I15?I35)/(I24?I35)??(1) wherein I15 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 15°, I35 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 35°, and I24 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 24°, is 1.4 or more; and an adsorbent for an oral administration, characterized by comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.

Abstract: The instant invention relates to shaped transition metal particles, in particular in the form of a dispersion in an aqueous and/or organic medium, the manufacture thereof and their use as an infrared (IR) absorbing agent, an IR curing agent for coatings, an additive in conductive formulations, an antimicrobial agent or for sensoring organic and/or inorganic compounds. Further, the invention relates to dispersions comprising said shaped particles and an aqueous and/or organic medium, such as a thermoplastic or crosslinkable polymer, as well as to antimicrobial compositions and products.

Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: The present invention includes a composition for implantation in a patient, comprising surface-functionalized nanodiamonds and at least one biodegradable biocompatible polymer. The present invention also includes a surgical fixation device for use in a patient.

Abstract: The invention is directed to a barrier composition, to a vehicle comprising said barrier composition, to a layer comprising said barrier composition, to a foodstuff comprising said vehicle or layer, to a pharmaceutical or nutraceutical composition comprising said vehicle or layer, to a method for protecting one or more active ingredients, and to the use of said barrier composition. The barrier composition of the invention comprises: a hydrophobic organic phase; and 0.1-75 vol. %, based on the total volume of the barrier composition, of biodegradable solid plate-like particles.

Abstract: The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention.

Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.

Abstract: A composite magnetic nanoparticle drug delivery system provides targeted controlled release chemotherapies for cancerous tumors and inflammatory diseases. The magnetic nanoparticle includes a biocompatible and biodegradable polymer, a magnetic nanoparticle, the biological targeting agent human serum albumin, and a therapeutic pharmaceutical composition. The composite nanoparticles are prepared by oil-in-oil emulsion/solvent evaporation and high shear mixing. An externally applied magnetic field draws the magnetic nanoparticles to affected areas. The biological targeting agent draws the nanoparticles into the affected tissues. Polymer degradation provides controlled time release delivery of the pharmaceutical agent.

Abstract: The present invention is a solution or colloid of fullerene, SWNTs, or graphene in cyclic terpenes, lactones, terpene-alcohol, fatty-acid alcohols, and lactones following ultrasonication and ultracentrifugation processing, for oil-energy, biological, electrical-thermal applications. The compositions are useful as fuel/oil/grease/gels (synthetic included), oil/fuel/additives/propellants, identification dyes, and heat-transfer fluids. Other functions are phase-change fluids for solar energy power plants, antifreeze, electronic dyes, electrolytic fluid/solvent, electrically-thermally conductive material for electrochemical, dielectric, filler/adhesive for semiconductor, eletro-optical, and liquid crystal substrates/coatings for touch sensitive transmissive or reflective displays. When combined with gelatin the formulations can function as dichroic-optical coatings for thin-films/waveguides/holograms.

Abstract: Nanocomposite fibers containing one or more carbon nanotubes encapsulated in an polysaccharide gel matrix.

Abstract: This disclosure is directed to a black effect pigment and a method of forming said pigment. The pigment comprises a platy substrate coated with SnO2 and/or SnO2 hydrates and Fe3O4 with an optional coating of metal oxides such as SiO2, TiO2, ZrO2 and ZnO2. The deposition of the SnO2 and/or SnO2 hydrates onto the substrate improves the adhesion and prepares the substrate surface for deposition of the iron oxides onto the platy surface, especially mica surfaces. While the pigment may be used in such applications as coating, powder coating, printing ink, plastic, ceramic material, glass, cosmetic formulation, laser marking pigment, pigment composition or dry preparation, the pigment is especially suitable for cosmetic applications.

Abstract: Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed. The invention includes a composition, comprising fibrous particles, wherein the fibrous particles include fibers and the fibers include calcium and pyrophosphate. Also included are methods for making calcium pyrophosphate particles wherein solutions of calcium salt and pyrophosphate salt are combined to form the particles. Pharmaceutical compositions and methods for treating a patent using the disclosed particles are also described.

Abstract: Methods for the treatment of asthma are provided, which comprise: (a) providing an implantable or insertable medical device that comprises an asthma treatment agent; and (b) inserting or implanting the medical device within the lungs (e.g., the trachea or the bronchial tree) of a patient, whereupon the therapeutic agent is delivered to the patient in an amount effective to reduce or eliminate the symptoms of asthma. Also disclosed herein are medical devices and kits for carrying out such methods.

Abstract: This invention provide processes for producing carboxylic acid product, along with useful salts. The carboxylic acid product that is produced according to this invention is preferably a C2-C12 carboxylic acid. Among the salts produced in the process of the invention are ammonium salts.

Abstract: The present invention provides adjuvant chemical compositions that increase the effectiveness of a wide array of agricultural chemicals. Specifically, the present adjuvant compositions may increase the effectiveness of the normal, accepted amounts of an agricultural chemical per acre. Alternatively, the present adjuvant compositions may obtain similar results upon application of a decreased amount an agricultural chemical per acre. Compositions are also provided that comprise, in addition to the adjuvant compositions, at least one agricultural chemical. The present invention further provides methods of preparation and use thereof.

Abstract: The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds.

Abstract: Natural, biodegradable compositions are described as well as methods for their manufacture. Fishing lures and other items made of the biodegradable materials disintegrate over time in fresh or salt water to reduce pollution. The materials are digestable by fish and other aquatic animals, reducing potential harm to the animal from ingesting a fishing lure or other item made from the natural biodegradable materials disclosed. Because the material is digestable, it can also be used as a food source or supplement for fish and aquatic animals.

Abstract: This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.

Abstract: Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilisation.

Abstract: A saline solution for a clinical or cosmetic use which consists essentially of a solution in water of sodium ions in major amount and potassium ions in minor amount, together with physiologically acceptable counter ions, being isotonic or optionally slightly hypertonic or hypotonic with respect to blood plasma or tears or an otherwise relevant biological fluid, and being substantially free of calcium ions, magnesium ions, phosphate ions, bicarbonate ions and also glucose, sucrose, food starch or other glucose-releasing saccharides, for use as a more cell-friendly alternative to normal saline.

Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.

Abstract: A pesticidal composition comprising a pesticide, an ammonium salt, and a nonionic surfactant, is provided.

Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

Abstract: The invention concerns a co-processed additive for a solid-dose pharmaceutical composition, the additive comprising from about 50% to 99.5% by weight of at least one pharmaceutical compression aid and from about 0.5% to 50% by weight of at least one pharmaceutical lubricant, the melting point of said compression aid(s) being higher than the melting point of said lubricant(s). The co-processed additive may be in the form of a physically bound composite whereby the lubricant is associated with the surface of the compression aid particles.

Abstract: The present invention relates to a method for the authentication of a product, comprising providing said product with at least one marker, wherein said marker is a phosphorescent marker selected from a set of m phosphorescent markers each having a different emission spectrum, wherein m is an integer equal or greater than 3, and wherein said marker is provided at an amount that results in a phosphor-specific emission below background radiation emitted from said product.